{"id":9,"date":"2025-11-19T23:36:52","date_gmt":"2025-11-19T22:36:52","guid":{"rendered":"https:\/\/fhucare.com\/governance-fhu-care2-2025-2030\/"},"modified":"2026-03-05T14:47:06","modified_gmt":"2026-03-05T13:47:06","slug":"governance-2025-2030","status":"publish","type":"page","link":"https:\/\/fhucare.com\/fr\/fhu-care2\/governance-2025-2030\/","title":{"rendered":"Governance 2025-2030"},"content":{"rendered":"\n

The governance structure comprises two committees : an Executive Committee<\/strong> and a Steering Committee<\/strong> , supported by an External Scientific Advisory Board<\/strong>.<\/p>\n\n\n\n

\n
\n
\n
\"\"<\/figure>\n\n\n\n

Samuel Bitoun<\/h3>\n\n\n\n

Coordinator (PI)<\/p>\n\n\n\n

Linked In<\/span><\/a> AP-HP<\/span><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n

Xavier Mariette<\/h3>\n\n\n\n

Vice coordinator <\/p>\n\n\n\n

AP-HP<\/span><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n

Camille Bigenwald<\/h3>\n\n\n\n

Vice coordinator<\/p>\n\n\n\n

Linked In<\/span><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n

L\u00e9o Pla\u00e7ais<\/h3>\n\n\n\n

Head of Clinical Research<\/p>\n\n\n\n

AP-HP<\/span><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n

Myriam Morcel <\/h3>\n\n\n\n

Manager FHU <\/p>\n\n\n\n

Clinical Research and Innovation Department (DRCI) of Greater Paris University Hospitals – AP-HP<\/p>\n\n\n\n

Linked In<\/span><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n\n\n\n

Diane Martinez<\/h3>\n\n\n\n

Head of the Transformation and Quality Management Department<\/p>\n\n\n\n

Clinical Research and Innovation Department (DRCI) of Greater Paris University Hospitals – AP-HP<\/p>\n\n\n\n

Linked In<\/span><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\"\"
Samuel Bitoun<\/a><\/strong>, MD, PhD, the project leader, has a double specialty of Rheumatology and Oncology, and defended a PhD thesis in Immunology. He served as CCA (Fellow) of the FHU CARE in 2020 and then as PHU in the immune-rheumatology department of Bicetre hospital led by Pr Xavier Mariette. Samuel Bitoun is an elected representative of assistant professor body on the board of the Paris-Saclay medical school. He is also part of a guideline committee at EULAR (European rheumatology society) that has emitted points to consider for the care of patients with Rheumatic diseases and Cancer. Finally, he is also part of the ACR (American College of Rheumatology \/EULAR) classification criteria joint committee for rheumatologic Immune adverse events of immune checkpoints. He is a member of the Steering committee of the MD, PhD Averroes program which helps medical pharmacy students and scientist from any field to perform high level research in various domains ranging from mathematics to biology, law and sociology. This program allows students to have access to any course in any field available at Paris-Saclay University. Pr Xavier Mariette continue to be involved in FHU CARE\u00b2 as a co-coordinator. For FHU CARE\u00b2, Samuel Bitoun <\/strong><\/a>takes over Xavier Mariette<\/strong><\/a>, the creator of the FHU CARE and of the DIM ITAC (Immunotherapy, Autoimmunity and Cancer). <\/em><\/p>\n\n\n\n

Executive Committee (9 members)<\/h2>\n\n\n\n
\n

Leadership :<\/h3>\n\n\n\n